Cost-utility of ranibizumab versus aflibercept for treating Greek patients with visual impairment due to diabetic macular edema
Crossref DOI link: https://doi.org/10.1186/s12962-016-0056-1
Published Online: 2016-04-14
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kourlaba, Georgia
Relakis, John
Mahon, Ronan
Kalogeropoulou, Maria
Pantelopoulou, Georgia
Kousidou, Olga
Maniadakis, Nikos
Funding for this research was provided by:
Novartis